Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Combination therapy with anti‐cytotoxic T lymphocyte‐associated protein 4 (CTLA‐4) and anti‐programmed death‐1 (PD‐1) monoclonal antibodies (mAbs) has dramatically improved the prognosis of patients with multiple types of cancer, including renal cell carcinoma (RCC). However, more than half of RCC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Tomofumi, Ishino, Takamasa, Ueda, Youki, Nagasaki, Joji, Sadahira, Takuya, Dansako, Hiromichi, Araki, Motoo, Togashi, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154808/
https://www.ncbi.nlm.nih.gov/pubmed/36762794
http://dx.doi.org/10.1111/cas.15756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154808/
https://www.ncbi.nlm.nih.gov/pubmed/36762794
http://dx.doi.org/10.1111/cas.15756

Ejemplares similares